Georgia's Medical Cannabis Program Faces Its Biggest Test as Crossover Day Deadline Hits

Georgia stands at the most consequential moment for medical cannabis since the program's creation. Senate Bill 220, the "Putting Georgia's Patients First Act," already passed the state Senate 39-17 and cleared a House committee by substitute on February 10, 2026. If enacted, it would raise THC limits tenfold, allow vaporization, and broaden qualifying conditions — transforming what has been one of America's most restrictive medical programs. A separate bill targeting marijuana-scent searches and a full recreational legalization proposal signal growing legislative appetite for cannabis reform across the political spectrum.

With approximately 33,700 active patients enrolled, 19 dispensaries operating, and Sine Die set for April 2, 2026, the window for action is narrow. However, as of Crossover Day on March 6, 2026, no marijuana legislation has received a House floor vote this session, casting real uncertainty over whether even the most popular bills will cross the finish line before the clock runs out.

The Scent Bill: HB 496 Faces an Uphill Battle

House Bill 496, introduced by Rep. Jasmine Clark (D-Lilburn), would prohibit law enforcement from using the smell of marijuana, burnt or unburnt, as the sole basis for stopping a person, searching a vehicle, seizing property, or making an arrest. The bill does not prevent officers from acting on marijuana odor combined with other evidence; it only bars scent as the singular justification.

The bill had a committee hearing before the House Judiciary Non-Civil Committee on February 25, 2026, where it drew passionate testimony from both sides. Yolanda Bennett of the Georgia Medical Cannabis Society and a registered medical marijuana patient testified about the burden on patients. "We are already sick and we're tired," Bennett said. "Just the inconvenience of having a police officer to go through our things. That's the thing you have to put in patients' point of view."

Rep. Clark argued the bill does not limit legitimate police practices but addresses a practical problem: legal hemp and illegal marijuana are both Cannabis sativa L. and produce indistinguishable odors. "You cannot distinguish between the two," Clark said. "We want to make sure that police officers are using something that is measurable, objective, verifiable, and not something that could get tied up in court."

Opposition came from prosecutors. Randy McGinley, district attorney for the Alcovy District, argued the bill limits police work by not allowing officers to rely on scent to see if other crimes are being committed. "We are saying law enforcement is saying they smell it, we are just not going to trust what they are saying in any situation," McGinley said.

The broader civil rights argument is compelling. According to the ACLU, Black Georgians are three times more likely to be arrested for marijuana possession despite nearly identical usage rates — a disparity that scent-based searches arguably exacerbate.

Current status: As of Crossover Day (March 6, 2026), HB 496 remains in the House Judiciary Non-Civil Committee. The committee vote was delayed from its originally expected date, and reporting indicates marijuana-related bills are not expected to receive floor votes before the Crossover deadline. Since HB 496 originated in the House and has not yet passed, it is effectively dead for this session unless it clears the chamber by midnight tonight or its language is later inserted into a "zombie bill" — a procedural maneuver where the text of a stalled bill is substituted into a bill that has already crossed over.

SB 220: Through Committee, But Awaiting a House Floor Vote

The centerpiece legislation of the 2025-2026 session is SB 220, sponsored by Sen. Matt Brass (R-Newnan) with 20 bipartisan co-sponsors. For a detailed breakdown of the bill's provisions, see our earlier analysis. This bill would transform Georgia's medical cannabis landscape in several critical ways:

• Raise the THC limit from 5% to 50%
• Allow vaporization and inhalation of cannabis oil (though not raw flower)
• Remove the requirement that conditions like cancer, Parkinson's, and multiple sclerosis be classified as "severe or end-stage" before patients qualify
• Add lupus as a new qualifying condition
• Establish reciprocity for out-of-state patients
• Allow caregivers to pick up products from pharmacies

The bill already cleared the Senate on March 6, 2025, with a convincing 39-17 vote. Floor amendments to weaken the bill failed decisively: an attempt to reduce the THC cap failed 12-43, an amendment to remove vaping failed 13-43, and an effort to strip PTSD and intractable pain as qualifying conditions failed 12-44. That strong Senate showing demonstrated genuine bipartisan support for medical expansion.

After the bill stalled in the House during the 2025 session and was withdrawn and recommitted on April 4, 2025, it received renewed attention in 2026. On February 10, 2026, the House Regulated Industries Committee favorably reported SB 220 by substitute, meaning the committee approved a modified version of the bill. This is a significant advancement, as the committee substitute represents the House's negotiated version of the legislation.

Current status: SB 220 has cleared committee but has not received a House floor vote. Because it already crossed over from the Senate in March 2025, it is not subject to the Crossover Day deadline. The bill remains alive and eligible for a House floor vote at any point before Sine Die on April 2, 2026. However, with over 200 bills stacked up in the House Rules Committee as of March 5, the legislative calendar is extremely crowded. The next four weeks will determine whether SB 220 reaches the House floor.

If the House passes SB 220 with its committee substitute (which may differ from the Senate-passed version), the bill would need to return to the Senate for concurrence or go to a conference committee to reconcile differences. All of this must happen before April 2.

Other Bills in Play

Several companion and alternative bills create additional legislative options, though most face even steeper odds:

HB 227 (House companion to SB 220): Passed the House 164-1 on February 27, 2025, but lacks the THC increase and vaping provisions. It focuses on removing "severe/end-stage" requirements and adding lupus. Pending in the Senate Health and Human Services Committee. Like SB 220, it already crossed over and remains eligible for action.

HB 440, the "PEACH Act" (Providing Effective Access to Cannabis for Health): The most expansive medical bill, which would allow all product forms including flower. It remains stalled in the House Health Committee with no movement and is unlikely to advance.

HB 1248, the "Georgia Cannabis Freedom and Integrity Act": The session's only recreational legalization bill, proposing adult-use possession of up to 2 ounces and home cultivation of 3 plants. It has received no committee action and is considered dead.

SB 33 and SB 254: Hemp regulation bills addressing delta-8 THC products and THC-infused beverages, both of which passed the Senate in 2025 and were revived in 2026. SB 254 was amended on the Senate floor by a narrow 29-27 vote to ban all THC-infused beverages entirely.

A House Blue Ribbon Study Committee on Medical Marijuana and Hemp Policies, chaired by physician-legislator Rep. Mark Newton (R-Augusta), held hearings throughout summer and fall 2025 at the Capitol, in Augusta, and at Mercer University in Macon, gathering testimony from patients, veterans, doctors, and industry stakeholders. That groundwork laid the foundation for the current legislative push.

33,700 Patients and 72 Access Points Define the Current Program

Georgia's medical cannabis program, governed by the Georgia Access to Medical Cannabis Commission (GMCC), has grown steadily but remains one of the nation's most restrictive. The program permits only low-THC oil, defined as containing no more than 5% THC by weight with at least an equal amount of CBD, in forms limited to tinctures, capsules, transdermal patches, lotions, lozenges, and nasal sprays. Smoking, vaping, edibles, and raw flower are all prohibited. Patients may possess up to 20 fluid ounces.

As of late 2025, the program's enrollment stands at approximately 33,700 active patients, 2,300 registered caregivers, and 700 participating physicians. More than 75% of registrants cite intractable pain or PTSD as their qualifying condition. Registration requires physician certification, costs $30 (plus a small service fee), and now provides a five-year card (extended from two years as of October 2024).

The retail infrastructure has expanded meaningfully. There are now 19 licensed dispensaries across the state, plus approximately 56 independent pharmacies authorized to dispense low-THC oil, making Georgia the first state to allow medical cannabis sales through independent pharmacies.

Six production licensees operate the supply chain. Trulieve and Botanical Sciences hold Class 1 licenses (up to 100,000 sq ft cultivation), while FFD GA Holdings (Fine Fettle), TheraTrue, Natures GA, and Treevana Remedy hold Class 2 licenses (up to 50,000 sq ft). Trulieve operates 6 dispensary locations, Botanical Sciences has 4, Fine Fettle has 4, TheraTrue operates 2, and Treevana has 1. The sole testing laboratory, SJ Labs and Analytics in Macon, handles all product testing.

Despite growth, the GMCC's 2026 annual report to the General Assembly acknowledged that "development of the industry continues to remain flat with little growth in the number of registered patients." Georgia's enrollment numbers are dwarfed by comparable Southern states: Mississippi and Louisiana each serve approximately 50,000 patients with smaller populations, and Florida's comprehensive program serves over 800,000.

Political Terrain: Bipartisan Support, But Institutional Drag

The political dynamics around Georgia cannabis legislation reveal a legislature willing to expand medical access but struggling with institutional inertia. Governor Brian Kemp signed the 2019 Hope Act creating the current program, calling it "carefully crafted" to "expand access for patients in need without opening the door to recreational drug use." He is explicitly opposed to recreational legalization and decriminalization but has not publicly opposed SB 220's medical expansion provisions. Kemp is term-limited and cannot seek reelection, which may reduce his influence on the issue in this session's final weeks.

Support for medical expansion is genuinely bipartisan. SB 220's Senate passage drew votes from both parties, and HB 227's near-unanimous 164-1 House vote demonstrates overwhelming support for at least some program improvements. House Speaker Jon Burns (R) listed medical marijuana among his 2026 session priorities.

Yet despite that stated priority, the House has not brought any marijuana bill to the floor as of March 6. This disconnect between stated support and actual floor action is the central tension of the 2026 session. Part of the explanation lies in the sheer volume of legislation competing for floor time, with over 200 bills queued for Crossover Day alone. Part may also reflect caution in an election year: every House member faces voters in the May 2026 primary, with candidate qualifying happening this same week.

External factors are creating additional pressure. A November 2025 federal budget deal included provisions restricting hemp products to 0.4mg THC per container, taking effect November 2026, potentially eliminating the unregulated hemp-derived THC market that many Georgia consumers currently rely on. President Trump's December 2025 executive order directing marijuana rescheduling from Schedule I to Schedule III does not change state law but may embolden reform-minded Republicans. Meanwhile, over 7,500 Georgians are arrested annually for marijuana possession, with roughly 90% for simple possession.

The most likely outcome: SB 220 gets a House floor vote in the remaining weeks before April 2, potentially with modifications from the committee substitute that could lower the THC cap from 50% as a compromise. But the possibility that it simply runs out of time is very real.

Georgia in the Context of a Shifting Southeast

Georgia's program occupies a middle position among its neighbors — more functional than most, but far less comprehensive than Florida's.

Tennessee has essentially no working medical program despite 81% voter support. South Carolina has no medical program; the Compassionate Care Act has twice passed the Senate only to die in the House. North Carolina lacks a functioning program, though the Eastern Band of Cherokee has sold adult-use cannabis on tribal land since 2024, and Governor Josh Stein has formed an advisory council on marijuana policy.

Alabama represents the most interesting comparison. Its 2021 medical law is broader than Georgia's in qualifying conditions and product forms (including gummies), but after years of licensing lawsuits, dispensary licenses were only approved in December 2025, with first sales expected in spring 2026. When Alabama becomes operational, it will further highlight the inadequacy of Georgia's 5% THC cap and limited product forms.

Florida operates in a different universe entirely, with over 800,000 patients, full-potency flower allowed at 2.5 ounces per 35 days, and an extensive dispensary network. Florida's 2024 recreational amendment received 56% support but fell short of the required 60% supermajority.

The broader Southeast trend shows accelerating change despite the region's conservative reputation. Virginia legalized adult-use cannabis in 2021. Every Georgia neighbor is either actively debating medical expansion or launching delayed programs. The combination of federal rescheduling momentum, the impending federal hemp-THC restriction, and growing patient enrollment creates what may be the strongest reform environment Georgia has seen.

What to Watch: The Next Four Weeks

The period between Crossover Day (March 6) and Sine Die (April 2) will determine whether Georgia's medical cannabis program takes its biggest step forward since inception. Here are the key things to watch:

SB 220's House floor vote. The bill has cleared committee by substitute and is eligible for a vote at any time. If the House passes a modified version, the Senate must concur or the two chambers will need to negotiate via conference committee — all before April 2.

The committee substitute details. The House Regulated Industries Committee approved SB 220 by substitute, meaning it may differ from the Senate-passed version. Whether the House version retains the 50% THC cap and vaping provisions will determine how transformative the final bill actually is.

Zombie bill potential. If HB 496 (the scent bill) does not cross over, watch for its language to potentially surface inside a bill that has already crossed chambers. This is a common Georgia legislative tactic.

Election year dynamics. With every House member facing voters in the May 2026 primary and candidate qualifying happening this week, lawmakers are simultaneously legislating and campaigning. This creates both urgency (to show accomplishments) and caution (to avoid controversial votes).

Georgia will not legalize recreational cannabis in 2026, but it has a realistic — if narrowing — path to joining the ranks of states with a genuinely functional medical program. For the 33,700 patients currently enrolled, and potentially many more who have been deterred by the program's current limitations, the next four weeks matter enormously.

---

Georgia Medical Cannabis Resources:

• Get Your Georgia Medical Cannabis Card
• Find a Georgia MMJ Doctor
• Georgia Qualifying Conditions
• Georgia Dispensary Directory
• Georgia Cannabis Prices
• Georgia MMJ Card Renewals
• Georgia Cannabis Laws
• Georgia SB 220: Full Analysis

---

Ready to access Georgia's medical cannabis program? MMJ.com connects Georgia patients with licensed physicians who can evaluate you for a medical cannabis card through convenient telehealth appointments. Get started today — registration is just $30 and your card is now valid for five years.